Meeting
2013 ASCO Annual Meeting
A phase III, randomized, double-blind study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus dacarbazine in patients (pts) with previously untreated, unresectable, or metastatic melanoma (MEL).
Authors
Caroline Robert
Institut Gustave Roussy, Villejuif, France
Caroline Robert , Paolo Antonio Ascierto , Michele Maio , Micaela Hernberg , Henrik Schmidt , Ian Waxman , Claus Garbe , Céleste Lebbé , Axel Hauschild
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Melanoma/Skin Cancers
Track
Melanoma/Skin Cancers
Sub Track
Melanoma/Skin Cancers
Clinical Trial Registration Number
NCT01721772
Citation
J Clin Oncol 31, 2013 (suppl; abstr TPS9106)
DOI
10.1200/jco.2013.31.15_suppl.tps9106
Abstract #
TPS9106
Poster Bd #
54C
Abstract Disclosures
Similar Posters
Poster
2013 ASCO Annual Meeting
A phase III open-label study of nivolumab (anti-PD-1; BMS-936558; ONO-4538) versus investigator’s choice in advanced melanoma patients progressing post anti-CTLA-4 therapy.
First Author: Bartosz Chmielowski
Poster
2022 ASCO Annual Meeting
Randomized phase 3 trial of IO102-IO103 plus pembrolizumab versus pembrolizumab alone in patients with previously untreated, unresectable, or metastatic melanoma.
First Author: Inge Marie Svane
Poster
2019 ASCO Annual Meeting
CA045-001: A phase III, randomized, open label study of bempegaldesleukin (NKTR-214) plus nivolumab (NIVO) versus NIVO monotherapy in patients (pts) with previously untreated, unresectable or metastatic melanoma (MEL).
First Author: Nikhil I. Khushalani
Poster
2016 ASCO Annual Meeting
Real-world overall survival in advanced melanoma from the IMAGE study.
First Author: Mark R. Middleton